Magnesium oxide: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
No edit summary
m (Protected "Magnesium oxide": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)))
 
(4 intermediate revisions by one other user not shown)
Line 1: Line 1:
{{DrugProjectFormSinglePage
{{DrugProjectFormSinglePage
|authorTag={{RB}}
|genericName=Magnesium oxide
|aOrAn=a
|aOrAn=a
|drugClass=[[antacid]]
|indicationType=treatment
|indicationType=treatment
|hasBlackBoxWarning=Yes
|indication=[[acid indigestion]], [[Abdominal pain|upset stomach]]
|adverseReactions=<!--Black Box Warning-->
|adverseReactions=[[diarrhea]], [[allergic reaction]]
 
 
<!--Black Box Warning-->
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningTitle=<span style="color:#FF0000;">ConditionName: </span>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>
|blackBoxWarningBody=<i><span style="color:#FF0000;">ConditionName: </span></i>


* Content


<!--Adult Indications and Dosage-->
<!--Adult Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Adult)-->
<!--FDA-Labeled Indications and Dosage (Adult)-->
|fdaLIADAdult======Condition1=====
|fdaLIADAdult=====Indications====
 
* Relieves: [[acid indigestion]], [[Abdominal pain|upset stomach]]
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
* Dosing Information
 
:* Dosage
 
=====Condition3=====
 
* Dosing Information
 
:* Dosage
 
=====Condition4=====
 
* Dosing Information
 
:* Dosage
 
<!--Off-Label Use and Dosage (Adult)-->
 
<!--Guideline-Supported Use (Adult)-->
|offLabelAdultGuideSupport======Condition1=====
 
* Developed by:


* Class of Recommendation:  
====Directions====
* Antacid Directions: (take 1 tablet twice a day or as directed by a physician


* Strength of Evidence:  
* Magnesium Supplement Directions: (take 1 to 2 tablets daily or as directed by a physician
 
|offLabelAdultGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Non–Guideline-Supported Use (Adult)-->
<!--Non–Guideline-Supported Use (Adult)-->
|offLabelAdultNoGuideSupport======Condition1=====
|offLabelAdultNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in adult patients.


<!--Pediatric Indications and Dosage-->
<!--Pediatric Indications and Dosage-->


<!--FDA-Labeled Indications and Dosage (Pediatric)-->
<!--FDA-Labeled Indications and Dosage (Pediatric)-->
|fdaLIADPed======Condition1=====
|fdaLIADPed=* Safety and efficacy in pediatrics patients has not been established.
 
|offLabelPedGuideSupport=There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>FDA-Labeled Use</i> of {{PAGENAME}} in pediatric patients.
 
<!--Off-Label Use and Dosage (Pediatric)-->
 
<!--Guideline-Supported Use (Pediatric)-->
|offLabelPedGuideSupport======Condition1=====
 
* Developed by:
 
* Class of Recommendation:
 
* Strength of Evidence:
 
* Dosing Information
 
:* Dosage
 
=====Condition2=====
 
There is limited information regarding <i>Off-Label Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


<!--Non–Guideline-Supported Use (Pediatric)-->
<!--Non–Guideline-Supported Use (Pediatric)-->
|offLabelPedNoGuideSupport======Condition1=====
|offLabelPedNoGuideSupport=There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.


* Dosing Information
<!--Contraindications-->
 
|contraindications=<!--Warnings-->
:* Dosage
|warnings=* Do Not Use
 
* Do not take more than 2 tablets in a 24 hour period or use the maximum dosage of this product for more than two weeks, except under the advice and supervision of a physician. May have a laxative effect.
=====Condition2=====


There is limited information regarding <i>Off-Label Non–Guideline-Supported Use</i> of {{PAGENAME}} in pediatric patients.
* Ask a Doctor if you have:
:* Kidney disease


<!--Contraindications-->
* Ask a Doctor/Pharmacist before use if you are:
|contraindications=* Condition1
:* Taking a prescription drug. Antacids may interact with certain prescription drugs.


<!--Warnings-->
* Pregnancy or Breast Feeding
|warnings=* Description
:* If pregnant or breast feeding, ask a health professional before use.


====Precautions====
* Keep Out of Reach of Children
 
* Description


<!--Adverse Reactions-->
<!--Adverse Reactions-->
Line 123: Line 58:
<!--Clinical Trials Experience-->
<!--Clinical Trials Experience-->
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
|clinicalTrials=There is limited information regarding <i>Clinical Trial Experience</i> of {{PAGENAME}} in the drug label.
=====Body as a Whole=====
=====Cardiovascular=====
=====Digestive=====
=====Endocrine=====
=====Hematologic and Lymphatic=====
=====Metabolic and Nutritional=====
=====Musculoskeletal=====
=====Neurologic=====
=====Respiratory=====
=====Skin and Hypersensitivy Reactions=====
=====Special Senses=====
=====Urogenital=====
=====Miscellaneous=====




<!--Postmarketing Experience-->
<!--Postmarketing Experience-->
|postmarketing=There is limited information regarding <i>Postmarketing Experience</i> of {{PAGENAME}} in the drug label.
|postmarketing=Laxative adverse reaction
 
|drugInteractions=<!--Use in Specific Populations-->
=====Body as a Whole=====
|useInPregnancyFDA=* If pregnant or breast feeding, ask a health professional before use.
 
 
 
=====Cardiovascular=====
 
 
 
=====Digestive=====
 
 
 
=====Endocrine=====
 
 
 
=====Hematologic and Lymphatic=====
 
 
 
=====Metabolic and Nutritional=====
 
 
 
=====Musculoskeletal=====
 
 
 
=====Neurologic=====
 
 
 
=====Respiratory=====
 
 
 
=====Skin and Hypersensitivy Reactions=====
 
 
 
=====Special Senses=====
 
 
 
=====Urogenital=====
 
 
 
=====Miscellaneous=====
 
 
 
<!--Drug Interactions-->
|drugInteractions=* Drug
:* Description
 
<!--Use in Specific Populations-->
|useInPregnancyFDA=* '''Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''
|useInPregnancyAUS=* '''Australian Drug Evaluation Committee (ADEC) Pregnancy Category'''


There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of {{PAGENAME}} in women who are pregnant.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInLaborDelivery=There is no FDA guidance on use of {{PAGENAME}} during labor and delivery.
|useInNursing=There is no FDA guidance on the use of {{PAGENAME}} with respect to nursing mothers.
|useInNursing=If pregnant or breast feeding, ask a health professional before use.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInPed=There is no FDA guidance on the use of {{PAGENAME}} with respect to pediatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
|useInGeri=There is no FDA guidance on the use of {{PAGENAME}} with respect to geriatric patients.
Line 264: Line 79:


<!--Administration and Monitoring-->
<!--Administration and Monitoring-->
|administration=* Oral
|administration=* [[Oral]]
 
* Intravenous
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.
|monitoring=There is limited information regarding <i>Monitoring</i> of {{PAGENAME}} in the drug label.


* Description


<!--IV Compatibility-->
<!--IV Compatibility-->
Line 275: Line 87:


<!--Overdosage-->
<!--Overdosage-->
|overdose====Acute Overdose===
|overdose=There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.


====Signs and Symptoms====
<!--Pharmacology-->


* Description
<!--Drug box 2-->
|drugBox={{Chembox2
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 414322178
| ImageFile = Magnesium chemb.png
| IUPACName = Magnesium oxide
| OtherNames = Magnesia<br/>[[Periclase]]
|Section1={{Chembox Identifiers
| CASNo = 1309-48-4
| CASNo_Ref = {{cascite|correct|CAS}}
| EINECS = 215-171-9
| PubChem = 14792
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1200572
| InChI =
| RTECS = OM3850000
| ATCCode_prefix = A02
| ATCCode_suffix = AA02
| ATC_Supplemental = {{ATC|A06|AD02}}, {{ATC|A12|CC10}}
}}
|Section2={{Chembox Properties
| Formula = MgO
| MolarMass = 40.3044 g/mol
| Appearance = White powder
| Odor = Odorless
| Density = 3.58 g/cm<sup>3</sup>
| MeltingPtC = 2852
| BoilingPtC = 3600
| Solubility = 0.00062 g/100 mL (0 °C) <br> 0.0086 g/100 mL (30 °C)
| SolubleOther = Soluble in [[acid]], [[ammonia]] <br> insoluble in [[alcohol]]
| ThermalConductivity = 45–60&nbsp;W·m<sup>−1</sup>·K<sup>−1</sup><ref>[http://www.konoshima.co.jp/en/resdev/004.html Application of magnesium compounds to insulating heat-conductive fillers]. konoshima.co.jp</ref>
| RefractIndex = 1.7355
| BandGap = 7.8 eV<ref>{{cite journal |journal=Solid State Communications |volume=55 |year=1985 |pages=351–5 |title=Self-consistent electronic structures of MgO and SrO |first1=O.E. |last1=Taurian |doi=10.1016/0038-1098(85)90622-2|last2=Springborg |first2=M. |last3=Christensen |first3=N.E. |issue=4 |url=http://users-phys.au.dk/nec/Papers/necSSC/SSC55351.pdf|bibcode = 1985SSCom..55..351T }}</ref>
| Dipole = 6.2 ± 0.6 D
}}
|Section3={{Chembox Structure
| CrystalStruct = [[Halite]] (cubic), [[Pearson symbol|cF8]]
| SpaceGroup = Fm<u style="text-decoration:overline">3</u>m, No. 225
| Coordination = Octahedral (Mg<sup>2+</sup>); octahedral (O<sup>2−</sup>)
| LattConst_a = 4.212Å
}}
|Section4={{Chembox Thermochemistry
| DeltaHf = −601.8&nbsp;kJ·mol<sup>−1</sup><ref name=b1>{{cite book |last=Zumdahl |first=Steven S. |title=Chemical Principles |edition=6th |publisher=Houghton Mifflin Company |year=2009 |isbn=0-618-94690-X |page=A22}}</ref>
| DeltaGf = -596.6 kJ/mol
| Entropy = 26.9&nbsp;J·mol<sup>−1</sup>·K<sup>−1</sup><ref name=b1/>
| HeatCapacity = 37.8 J/mol K
}}
|Section5={{Chembox Hazards
| ExternalMSDS = [http://www.inchem.org/documents/icsc/icsc/eics0504.htm ICSC 0504]
| EUIndex = Not listed
| EUClass =
| RPhrases = {{R36}}, {{R37}}, {{R38}}
| SPhrases =
| MainHazards = [[Metal fume fever]], Irritant
| NFPA-H = 1
| NFPA-F = 0
| NFPA-R = 0
| NFPA-O =
| FlashPt = Non-flammable
| LD50 =
| PEL = TWA 15 mg/m<sup>3</sup> (fume)<ref name=PGCH/>
| REL = None designated<ref name=PGCH/>
| IDLH = 750 mg/m<sup>3</sup> (fume)<ref name=PGCH>{{PGCH|0374}}</ref>
}}
|Section6={{Chembox Related
| OtherAnions = [[Magnesium sulfide]]
| OtherCations = [[Beryllium oxide]]<br/>[[Calcium oxide]]<br/>[[Strontium oxide]]<br/>[[Barium oxide]]
| OtherFunctn =
| Function =
| OtherCpds = [[Magnesium hydroxide]]<br/>[[Magnesium nitride]]
}}
}}


====Management====


* Description


===Chronic Overdose===
<!--Mechanism of Action-->
|mechAction=*


There is limited information regarding <i>Chronic Overdose</i> of {{PAGENAME}} in the drug label.
<!--Structure-->
 
|structure=* ACTIVE INGREDIENTS
<!--Pharmacology-->
: Magnesium Oxide 400mg (241.3mg elemental magnesium)


<!--Drug box 2-->
* INACTIVE INGREDIENTS
|drugBox=<!--Mechanism of Action-->
: Colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, stearic acid
|mechAction=*


<!--Structure-->
|structure=*


: [[File:{{PAGENAME}}01.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]


<!--Pharmacodynamics-->
<!--Pharmacodynamics-->
Line 313: Line 192:


<!--How Supplied-->
<!--How Supplied-->
|howSupplied=*
|howSupplied=* do not use if imprinted safety seal under cap is broken or missing
|packLabel=<!--Patient Counseling Information-->
* Magnesium content per tablet: 240 mg
|storage=* store at room temperature 59°-86° F (15°-30°C)
|packLabel=====PRINCIPAL DISPLAY PANEL====
: [[File:Magnesium PDP.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
 
====Ingredients and Appearance====
: [[File:Magnesium I n A.png|thumb|none|600px|This image is provided by the National Library of Medicine.]]
<!--Patient Counseling Information-->
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.
|fdaPatientInfo=There is limited information regarding <i>Patient Counseling Information</i> of {{PAGENAME}} in the drug label.


Line 321: Line 207:


<!--Brand Names-->
<!--Brand Names-->
|brandNames=* ®<ref>{{Cite web | title = | url = }}</ref>
|brandNames=* MagGel®<ref>{{Cite web | title = Magnesium oxide | url = http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d3c5b01b-f0d6-4503-ab18-b1a72386e2c6}}</ref>


<!--Look-Alike Drug Names-->
<!--Look-Alike Drug Names-->
|lookAlike=* A® — B®<ref name="www.ismp.org">{{Cite web  | last =  | first =  | title = http://www.ismp.org | url = http://www.ismp.org | publisher =  | date =  }}</ref>
|lookAlike=There is limited information regarding look alike drug names.
 
<!--Drug Shortage Status-->
|drugShortage=
|drugShortage=
}}
}}
{{PillImage
|fileName=No image.jpg
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
{{LabelImage
|fileName={{PAGENAME}}11.png
}}
<!--Pill Image-->
<!--Label Display Image-->




Latest revision as of 16:38, 20 August 2015

Magnesium oxide
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rabin Bista, M.B.B.S. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Magnesium oxide is a antacid that is FDA approved for the treatment of acid indigestion, upset stomach. Common adverse reactions include diarrhea, allergic reaction.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Directions

  • Antacid Directions: (take 1 tablet twice a day or as directed by a physician
  • Magnesium Supplement Directions: (take 1 to 2 tablets daily or as directed by a physician

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Magnesium oxide in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Magnesium oxide in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

  • Safety and efficacy in pediatrics patients has not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Magnesium oxide in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Magnesium oxide in pediatric patients.

Contraindications

There is limited information regarding Magnesium oxide Contraindications in the drug label.

Warnings

  • Do Not Use
  • Do not take more than 2 tablets in a 24 hour period or use the maximum dosage of this product for more than two weeks, except under the advice and supervision of a physician. May have a laxative effect.
  • Ask a Doctor if you have:
  • Kidney disease
  • Ask a Doctor/Pharmacist before use if you are:
  • Taking a prescription drug. Antacids may interact with certain prescription drugs.
  • Pregnancy or Breast Feeding
  • If pregnant or breast feeding, ask a health professional before use.
  • Keep Out of Reach of Children

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Clinical Trial Experience of Magnesium oxide in the drug label.

Postmarketing Experience

Laxative adverse reaction

Drug Interactions

There is limited information regarding Magnesium oxide Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA):

  • If pregnant or breast feeding, ask a health professional before use.


Pregnancy Category (AUS):

  • Australian Drug Evaluation Committee (ADEC) Pregnancy Category

There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Magnesium oxide in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Magnesium oxide during labor and delivery.

Nursing Mothers

If pregnant or breast feeding, ask a health professional before use.

Pediatric Use

There is no FDA guidance on the use of Magnesium oxide with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Magnesium oxide with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Magnesium oxide with respect to specific gender populations.

Race

There is no FDA guidance on the use of Magnesium oxide with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Magnesium oxide in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Magnesium oxide in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Magnesium oxide in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Magnesium oxide in patients who are immunocompromised.

Administration and Monitoring

Administration

Monitoring

There is limited information regarding Monitoring of Magnesium oxide in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Magnesium oxide in the drug label.

Overdosage

There is limited information regarding Chronic Overdose of Magnesium oxide in the drug label.

Pharmacology

Template:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox entryTemplate:Chembox ECNumberTemplate:Chembox E numberTemplate:Chembox RTECSTemplate:Chembox AppearanceTemplate:Chembox OdourTemplate:Chembox DensityTemplate:Chembox MeltingPtTemplate:Chembox BoilingPtTemplate:Chembox SolubilityInWaterTemplate:Chembox SolubilityTemplate:Chembox BandGapTemplate:Chembox ThermalConductivityTemplate:Chembox RefractIndexTemplate:Chembox DipoleTemplate:Chembox StructureTemplate:Chembox ThermochemistryTemplate:Chembox MainHazardsTemplate:Chembox RPhrasesTemplate:Chembox NFPATemplate:Chembox FlashPtTemplate:Chembox NIOSH (set)Template:Chembox OtherAnionsTemplate:Chembox OtherCationsTemplate:Chembox Supplement
Template:Chembox header2 | Magnesium oxide
Identifiers
ChEMBL
ECHA InfoCard Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value). Lua error in Module:Wikidata at line 879: attempt to index field 'wikibase' (a nil value).
Properties
MgO
Molar mass 40.3044 g/mol
Hazards
Related compounds
Template:Chembox header2 | Except where noted otherwise, data are given for
materials in their standard state
(at 25 °C, 100 kPa)
Infobox disclaimer and references

Mechanism of Action

Structure

  • ACTIVE INGREDIENTS
Magnesium Oxide 400mg (241.3mg elemental magnesium)
  • INACTIVE INGREDIENTS
Colloidal silicon dioxide, croscarmellose sodium, microcrystalline cellulose, stearic acid

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Magnesium oxide in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Magnesium oxide in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Magnesium oxide in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Magnesium oxide in the drug label.

How Supplied

  • do not use if imprinted safety seal under cap is broken or missing
  • Magnesium content per tablet: 240 mg

Storage

  • store at room temperature 59°-86° F (15°-30°C)

Images

Drug Images

{{#ask: Page Name::Magnesium oxide |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

PRINCIPAL DISPLAY PANEL

This image is provided by the National Library of Medicine.

Ingredients and Appearance

This image is provided by the National Library of Medicine.

{{#ask: Label Page::Magnesium oxide |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Magnesium oxide in the drug label.

Precautions with Alcohol

  • Alcohol-Magnesium oxide interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

Look-Alike Drug Names

There is limited information regarding look alike drug names.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

  1. ↑ Taurian, O.E.; Springborg, M.; Christensen, N.E. (1985). "Self-consistent electronic structures of MgO and SrO" (PDF). Solid State Communications. 55 (4): 351–5. Bibcode:1985SSCom..55..351T. doi:10.1016/0038-1098(85)90622-2.
  2. ↑ Application of magnesium compounds to insulating heat-conductive fillers. konoshima.co.jp
  3. ↑ 3.0 3.1 3.2 Template:PGCH
  4. ↑ "Magnesium oxide".
Retrieved from "https://www.wikidoc.org/index.php?title=Magnesium_oxide&oldid=1136967"